BMJ Open Maximum blood glucose levels during hospitalisation to predict mortality in patients with acute coronary syndrome: a retrospective cohort study

Jun Qian,¹ Lijun Kuang,² Lin Che,¹ Fei Chen,¹ Xuebo Liu ¹

To cite: Qian J, Kuang L, Che L, *et al.* Maximum blood glucose levels during hospitalisation to predict mortality in patients with acute coronary syndrome: a retrospective cohort study. *BMJ Open* 2020;**10**:e042316. doi:10.1136/bmjopen-2020-042316

► Prepublication history and supplemental material for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-042316>).

Received 01 July 2020

Revised 21 November 2020

Accepted 24 November 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Cardiology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China

²Department of Ultrasound, Luwan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence to

Dr Xuebo Liu;
liuxb70@126.com and
Dr Fei Chen;
riverapt@126.com

ABSTRACT

Objective The aim in this study was to stratify maximum blood glucose levels to identify the best cut-off value of glucose levels to predict mortality in acute coronary syndrome (ACS) patients, regardless of whether they had diabetes.

Design A retrospective cohort study.

Setting All clinical data were obtained from the 'Medical Information Mart for Intensive Care III' database.

Participants A total of 3078 patients with ACS were included in the study. We divided the patients into four levels based on their maximum blood glucose levels (glucose_{max}), then analysed the relationship between each group with mortality.

Results Among enrolled patients, 2780 and 298 were survivors and non-survivors, respectively. Blood glucose levels and mortality showed a 'tick' type relationship, with levels 3 and 4 found to be closely associated with increased hospital mortality ($p < 0.05$), relative to level 1 (< 6.1 mmol/L), used as the reference group. No significant association was observed in mortality between level 2 and level 1 ($p = 0.095$). In addition, we found a gradual increase in OR for level 2 (OR: 2.42, 95% CI 0.86 to 6.80, $p = 0.095$), level 3 (OR: 4.33, 95% CI 1.55 to 12.13, $p = 0.005$) and level 4 (OR: 7.27, 95% CI 2.56 to 20.62, $p < 0.001$), relative to level 1. Based on receiver operating characteristic curves, the optimal cut-off value for predicting mortality were 11.5 (area under curve (AUC)=0.724), 11.2 (AUC=0.729), 13.4 (AUC=0.638), 15.8 (AUC=0.717) and 11.3 mmol/L (AUC=0.764) in all ACS, acute myocardial infarction, unstable angina, diabetes and non-diabetes patients, respectively. The results of subgroup analysis suggested that in patients with significantly elevated blood glucose, the mortality of non-diabetes was higher than patients with diabetes (OR: 0.42, 95% CI 0.31 to 0.57, $p < 0.001$).

Conclusion Overall, glucose_{max} ≥ 11.5 mmol/L had a significant association with increased mortality in patients with ACS. Non-diabetes ACS patients need a more robust blood glucose management strategy compared with diabetes counterparts.

INTRODUCTION

Acute coronary syndrome (ACS) is mainly caused by coronary artery disease occlusion and can range from unstable angina (UA) to ST segment elevation myocardial infarction.¹

Strengths and limitations of this study

- All data were extracted from a public open-access database.
- Subgroup analysis based on the disease contribute to dissect the influencing factor.
- The best cut-off value of blood glucose to predict mortality was identified to the disease subgroup.
- The maximum blood glucose might be influenced by several factors that may cause a deviation in the conclusion.
- Due to the retrospective design of the study, causality cannot be inferred from the results.

Patients with ACS commonly exhibit hyperglycaemia, although the relationship between these conditions is complex. Numerous studies have demonstrated occurrence of hyperglycaemia in critically ill patients, irrespective of whether they have diabetes.²⁻⁴ A previous study, analysing patients with acute coronary heart disease, found that 58% of them exhibited impaired glucose regulation, compared with 51% in the stable patients.⁵ The adverse effects of hyperglycaemia in ACS have been widely studied.⁶⁻⁸ In addition, several studies have confirmed that hyperglycaemia is an independent factor for ACS prognosis, although the mechanism between elevated blood glucose levels and poor ACS prognosis remains unclear.^{9 10} For example, Foo *et al*¹¹ stratified the relationship between blood glucose and cardiogenic death based on admission blood glucose levels but did not determine a blood glucose threshold for predicting hospital mortality. Furthermore, the optimal glucose cut-off value for predicting mortality in patients with ACS is also controversial, with some studies reporting a 2.2-fold increase in risk of shock when the admission blood glucose was higher than 11.5 mmol/L.¹² For non-ST-segment elevation myocardial infarction patients, 8.2 mmol/L

was previously shown to be the optimal admission glucose cut-off value for predicting outcomes.¹³ However, no study has reported the optimal cut-off value for maximum blood glucose to predict adverse outcomes, despite its potential in predicting prognosis.

The relationship between blood glucose levels and mortality in patients with ACS also remains unclear. Previous studies have shown that acute or stress hyperglycaemia may promote and exacerbate the outcomes of cell damage caused by myocardial ischaemia in patients with ACS.¹⁴ Furthermore, hyperglycaemia-induced oxidative stress may activate platelet-related signalling pathways, leading to platelet aggregation and formation of atherosclerotic plaque.¹⁵ Nevertheless, the evidence on maximum blood glucose levels and mortality remains to be validated. Our study sought to evaluate the potential for levels of blood glucose as an important prognostic factor for mortality in patients with ACS, regardless of whether they had diabetes. Specifically, maximum blood glucose levels were analysed in patients to ascertain the optimal cut-off value for predicting hospital mortality. We also performed subgroup analysis based on the type of ACS and whether patients had diabetes to identify the relationship between different disease states and mortality.

MATERIAL AND METHODS

Data access

All patient data were downloaded from the Medical Information Mart for Intensive Care III database V.1.4.¹⁶ The database comprises comprehensive clinical information of inpatients at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts from 1 June 2001 to 31 October 2012. The use of this database was approved by the BIDMC Institutional Review Board; therefore, we did not require an ethical approval statement and informed consent for this study. Since any researcher who has completed the 'Protecting of Human Subjects' training can access the database, our data extraction processes were performed by JQ, following completion of the National Institutes of Health online training course (certificate code: 32299459).

Study population

We first screened 3221 patients with ACS and included all patients admitted with ACS. We excluded 143 patients, due to repeated admissions and missing data, as well as pregnant women and patients younger than 18 years old. Finally, a total of 3078 patients, including 2011 patients with acute myocardial infarction (AMI) and 1067 patients with UA were enrolled in the study. Information extracted from the database included age, sex, comorbidities, medications used and laboratory tests performed on admission, Sequential Organ Failure Assessment (SOFA) score, detailed records of blood glucose during hospitalisation, hospital and intensive care unit (ICU) mortality, as well as hospital and ICU length of stay (LOS). The

blood glucose of each patient was measured three to four times during hospitalisation. The first blood glucose at admission was defined as the initial blood glucose, and the maximum blood glucose was selected as the research object of this article. Initial and maximum serum glucose levels were denoted as glucose₀ and glucose_{max}, respectively. Thereafter, max blood glucose was divided into the following groups based on clinical experience: level 1 (<6.1 mmol/L), level 2 (6.1–11.1 mmol/L), level 3 (11.1–16.6 mmol/L) and level 4 (≥16.6 mmol/L), with level 1 used as reference group.

Outcomes and definitions

The primary outcome was defined as hospital mortality, whereas other outcomes were defined as ICU mortality, hospital and ICU LOS, as well as acute kidney injury. Data for the first ICU stay alone was extracted, whereas acute kidney injury was defined as serum creatinine levels that were 1.5 times higher than the baseline.¹⁷

Statistical analysis

Statistical analyses were performed using Stata V.13.1 and SPSS V.23.0 software. Specifically, continuous variables were expressed as means±SD, with Student's t-test, Wilcoxon rank-sum or Kruskal-Wallis tests used accordingly. However, categorical variables were presented as percentages, then comparisons made using the χ^2 or Fisher's exact tests. In addition, the lowess smoothing algorithm was used to show the rough relationship between blood glucose and mortality. Due to the large number of variables in this study, we first used univariate logistic regression for initial screening of influencing factors, then selected resulting variables with $p < 0.05$ for multivariate logistic regression, with level 1 of the blood glucose used as the reference group. The forward likelihood method and $p < 0.05$ were used to build the final regression model. In addition, receiver operating characteristic (ROC) curves were used to predict mortality during hospitalisation across different disease groups and also determine the cut-off value. Significance level was set at 0.05 level, and all analyses were two sided.

Patient and public involvement

No patient was involved in any part of this study.

RESULTS

Among the 3078 patients with ACS included in the study, 2780 and 298 were survivors and non-survivors, respectively, with a hospital mortality of 9.8%. A summary of baseline characteristics for the study cohort is outlined in [table 1](#). All demographic characteristics revealed significant differences between survivors and non-survivors, except in prior myocardial infarction, diabetes, chronic obstructive pulmonary disease and cerebral infarction. In addition, significantly lower ($p < 0.05$) glucose₀, glucose_{max} and glucose_{min} were recorded in survivors at 8.2 ± 3.8 , 10.9 ± 5.0 and 5.1 ± 1.4 mmol/L, respectively,

Table 1 Baseline characteristics of demographics between survivors and non-survivors

Variable	Survivors (n=2780)	Non-survivors (n=298)	P value
Age (years)	67±13	74±13	<0.001
Male, n (%)	1870 (67.3)	163 (54.7)	<0.001
ACS categories, n (%)			<0.001
AMI	1733 (62.3)	278 (93.3)	
UA	1047 (37.7)	20 (6.7)	
Comorbidities, n (%)			
Prior MI	271 (9.7)	25 (8.4)	0.535
Hypertension	1535 (55.2)	126 (42.3)	<0.001
Diabetes	842 (30.3)	85 (28.5)	0.550
Heart failure	886 (31.9)	146 (49.0)	<0.001
Hyperlipidaemia	768 (27.6)	54 (18.1)	<0.001
COPD	32 (1.2)	5 (1.7)	0.398
Atrial fibrillation	712 (25.6)	113 (37.9)	<0.001
Cerebral infarction	90 (3.2)	15 (5.0)	0.127
Admission drugs, n (%)			
Aspirin	1438 (51.7)	100 (33.6)	<0.001
ACE inhibitor	1217 (43.8)	48 (16.1)	<0.001
β blocker	2111 (75.9)	110 (36)	<0.001
Clopidogrel	590 (21.2)	45 (15.1)	0.013
Diuretic	1526 (54.9)	124 (41.6)	<0.001
Statin	1323 (47.6)	58 (19.5)	<0.001
Insulin	1299 (46.7)	98 (32.9)	<0.001
Oral hypoglycaemic agents	191 (6.9)	2 (0.7)	<0.001
Initial laboratory data			
WCC, 10 ³ /μL	11.4±4.8	14.4±7.5	<0.001
Haemoglobin, mg/dL	11.7±2.1	11.2±2.1	0.001
Creatinine, mg/dL	1.1±1.0	1.7±1.4	<0.001
SOFA score	3.6±2.7	6.9±3.7	<0.001
Serum glucose, mmol/L			
Glucose ₀	8.2±3.8	11.3±6.3	<0.001
Glucose _{max}	10.9±5.0	15.6±7.5	<0.001
Glucose _{min}	5.1±1.4	6.0±3.6	<0.001

ACS, acute coronary syndrome; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; glucose₀, initial glucose after intensive care unit admission; glucose_{max}, maximum glucose during ICU stay; glucose_{min}, mean glucose during ICU stay; MI, myocardial infarction; SOFA, sequential organ failure assessment; UA, unstable angina; WCC, white cell count.

than non-survivors who recorded 11.3±6.3, 15.6±7.5 and 6.0±3.6 mmol/L, respectively. We also divided patients with ACS into AMI group and UA group, and diabetes group and non-diabetes group, and analysed baseline characteristics of two groups, respectively (online supplemental tables 1 and 2). We found that the mortality of

Figure 1 Association between maximum glucose levels and hospital mortality in groups of different diseases.

AMI was significantly higher than patients with UA, as well as the blood glucose levels (all $p<0.001$). However, although the blood glucose level of the diabetes group was significantly higher than non-diabetes group ($p<0.001$), there was no difference in mortality between two groups ($p=0.528$).

Analysis of data from ACS patients with or without diabetes revealed a rough relationship between serum glucose_{max} and hospital mortality across different diseases (figure 1). Generally, the relationship was 'tick' shaped (figure 1A, B, D and E), except in the UA group (figure 1C). A summary of the relationship between glucose_{max} categories and end points is provided in table 2. Particularly, patients with elevated glucose_{max} levels had significantly higher rates of unadjusted hospital and ICU mortality ($p<0.001$). In addition, high glucose_{max} levels were associated with longer hospital and ICU LOS, as well as acute kidney injury (all $p<0.001$).

Results from univariate and multivariate logistic regression analyses used to predict mortality are outlined in table 3. Summarily, the univariate logistic model revealed that age, male, AMI, hypertension, heart failure, hyperlipidaemia, atrial fibrillation, aspirin, ACE inhibitor (ACEI), β blocker, clopidogrel, diuretic, statin, insulin, oral hypoglycaemic agents, white cell count (WCC), haemoglobin, creatinine, SOFA score and glucose_{max} categories were all predictors of hospital mortality. After adjusting for covariates, multivariate logistic regression results showed that age, AMI, atrial fibrillation, ACEI, β blocker, statin, oral hypoglycaemic agents, WCC, SOFA scores and glucose_{max} were all independent predictors of hospital mortality. Analysis of the relationship between glucose_{max} categories and mortality revealed that level 3 and level 4 were both associated with increased hospital mortality ($p<0.05$), relative to level 1 (<6.1 mmol/L) set as the reference group. However, we found no significant difference in mortality between level 2 and level 1 ($p=0.095$). We also found a gradual increase in OR for level 2 (OR: 2.42, 95% CI 0.86 to 6.80, $p=0.095$), level 3 (OR: 4.33, 95% CI 1.55 to 12.13, $p=0.005$) and level 4 (OR: 7.27, 95% CI 2.56 to 20.62, $p<0.001$) relative to level 1.

Finally, we used ROC curves to assess the predictive utility of glucose_{max} in hospital mortality and determine the optimal cut-off value. Results indicated that optimal

Table 2 Unadjusted outcomes by maximum glucose categories in patients with ACS

Outcomes	Glucose _{max} categories (mmol/L)				P value
	<6.1 (n=177)	6.1–11.1 (n=1683)	11.1–16.6 (n=865)	≥16.6 (n=353)	
Hospital mortality, n (%)	5 (2.8)	82 (4.9)	112 (12.9)	99 (28.0)	<0.001
ICU mortality, n (%)	2 (1.1)	58 (3.4)	77 (8.9)	74 (21.0)	<0.001
Hospital LOS, mean±SD (days)	3.3±1.7	6.7±1.7	9.4±8.5	12.3±12.3	<0.001
ICU LOS, mean±SD (days)	1.6±1.5	2.8±3.5	4.5±6.6	6.5±8.2	<0.001
AKI, n (%)	2 (1.1)	177 (10.5)	176 (20.3)	113 (32.0)	<0.001

ACS, acute coronary syndrome; AKI, acute kidney injury; Glucose_{max}, maximum serum glucose during hospital stay; ICU, intensive care unit; LOS, length of stay.

cut-off values were 11.5 (area under curve (AUC)=0.724), 11.2 (AUC=0.729), 13.4 (AUC=0.638), 15.8 (AUC=0.717) and 11.3 mmol/L (AUC=0.764) for all ACS, AMI, UA, diabetes and non-diabetes patients, respectively (figure 2). To further identify the difference between diabetes and non-diabetes with mortality, we performed a subgroup analysis of the two groups (figure 3 and online supplemental table 3). Interestingly, we found that except for patients with significantly elevated blood

glucose (≥11.1 mmol/L), subgroup analysis of diabetes and non-diabetes indicated other factors were not statistically significant with hospital mortality. Among patients with blood glucose_{max} levels ≥11.1 mmol/L, the mortality of non-diabetes patients was significantly higher than diabetes patients (OR: 0.42, 95% CI 0.31 to 0.57, p<0.001). However, in patients with blood glucose_{max} <11.1 mmol/L, there was no significant difference in mortality between the two groups (OR: 0.98, 95% CI 0.55 to 1.76, p=0.96).

Table 3 Effects of variables on hospital mortality in univariate and multivariate logistic regression analysis in all patients with ACS

Variables	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Age	1.05 (1.04 to 1.06)	<0.001	1.04 (1.03 to 1.05)	<0.001
Male	0.56 (0.46 to 0.75)	<0.001		0.625
AMI (UA as ref)	8.40 (5.30 to 13.30)	<0.001	5.71 (3.50 to 9.31)	<0.001
Hypertension	0.59 (0.47 to 0.76)	<0.001	–	0.897
Heart failure	2.05 (1.61 to 2.61)	<0.001	–	0.774
Hyperlipidaemia	0.58 (0.43 to 0.79)	<0.001	–	0.075
Atrial fibrillation	1.78 (1.38 to 2.28)	<0.001	1.47 (1.08 to 2.00)	0.015
Aspirin	0.47 (0.37 to 0.61)	<0.001	–	0.504
ACEI	0.25 (0.18 to 0.34)	<0.001	0.40 (0.27 to 0.60)	<0.001
β blocker	0.19 (0.14 to 0.24)	<0.001	0.49 (0.34 to 0.71)	<0.001
Clopidogrel	0.66 (0.48 to 0.92)	0.014	–	0.618
Diuretic	0.59 (0.46 to 0.75)	<0.001	–	0.145
Statin	0.26 (0.20 to 0.36)	<0.001	0.57 (0.39 to 0.83)	0.004
Insulin	0.56 (0.43 to 0.72)	<0.001		0.961
Oral hypoglycaemic agents	0.09 (0.02 to 0.37)	0.001	0.23 (0.05 to 0.95)	0.042
WCC	1.09 (1.07 to 1.12)	<0.001	1.06 (1.03 to 1.08)	<0.001
Haemoglobin	0.91 (0.86 to 0.96)	0.001	–	0.160
Creatinine	1.37 (1.26 to 1.48)	<0.001	–	0.159
SOFA score	1.36 (1.31 to 1.41)	<0.001	1.25 (1.19 to 1.30)	<0.001
Glucose _{max} (<6.1)	Ref.	<0.001	Ref.	<0.001
Glucose _{max} (6.1–11.1)	1.76 (0.71 to 4.41)	0.23	2.42 (0.86 to 6.80)	0.095
Glucose _{max} (11.1–16.6)	5.12 (2.06 to 12.73)	<0.001	4.33 (1.55 to 12.13)	0.005
Glucose _{max} (≥16.6)	13.41 (5.35 to 33.61)	<0.001	7.27 (2.56 to 20.62)	<0.001

ACEI, ACE inhibitor; ACS, acute coronary syndrome; AMI, acute myocardial infarction; SOFA, sequential organ failure assessment; UA, unstable angina; WCC, white cell count.

Figure 2 The glucose_{max} during hospitalisation level ROC curve for hospital mortality in groups of different diseases. AUC, area under curve; ROC, receiver operating characteristic.

DISCUSSION

Results from our study revealed an association between maximum glucose levels and increased hospital mortality in patients with ACS, as evidenced by a ‘tick’-shaped relationship. In addition, we determined optimal cut-off values for the maximum blood glucose during hospitalisation that could contribute to predict hospital mortality across different disease groups. We also performed subgroup analysis of whether patients with ACS had diabetes to clarify the relationship with mortality. Previous

studies have reported a gradual increase in mortality of ACS patients with increase in blood glucose.^{11 18 19} However, our findings indicated that hospital mortality first decreased, then increased with a gradual increase in blood glucose levels, except in patients with UA. This weakened trend could be due to the small number of patients in the UA group. When the blood glucose level fluctuates within a more normal range, the mortality of patients was relatively lowest. In the diabetic group, blood glucose levels corresponding to the death rate moved backward as a whole. However, when the blood glucose level was significantly increased (≥ 11.1 mmol/L), the mortality was positively correlated with the blood glucose levels. Glucose variability is important, and the elevated glucose (maximum glucose) may be one part of the glucose fluctuation. These findings are consistent with a previous study by Gerbaud *et al*²⁰, which reported significant fluctuations of glucose was associated with cardiovascular outcomes.

The relationship between hyperglycaemia and adverse events in patients with ACS is not clear. For example, previous studies have shown that stress hyperglycaemia is produced through activation of the sympathetic nervous system and the hypothalamic–pituitary axis, leading to increased production of catecholamines and cortisol, as well as stimulating gluconeogenesis, glycogenolysis and lipolysis.^{21 22} Other studies have demonstrated that insulin-mediated reduction of blood glucose concentrations during ACS could reduce mortality.²³ In addition, insulin treatment have been found to reduce inflammatory factors and coagulation media in plasma, thereby improving endothelial function and reducing the infarct size in patients with ACS.^{24 25} A large number of prospective studies analysing insulin in patients with ACS have reported varying degrees of benefit, although in the context of ACS, continuous insulin infusion is only recommended when blood glucose levels are higher than 10/11 mmol/L (180/200 mg/dL).^{26 27} In the current study, OR results indicated that insulin was a protective factor for hospital mortality in ACS, although this effect disappeared after adjusting for covariates, possibly due to a limited sample size.

Several studies have shown that patients with higher blood glucose levels exhibit increased 30-day and 1-year mortality, after multivariate adjustment of confounding factors, including age, sex, previous vascular events, hypertension, smoking status, Killip grade and atrial fibrillation, relative to those with a glucose concentration up to 6.1 mmol/L on admission.^{10 28} This trend was also observed in the current study. Results from the multivariate logistic regression analysis revealed that age, AMI (vs UA), atrial fibrillation, ACEI, β blocker, statin, oral hypoglycaemic agents, WCC, SOFA score and glucose_{max} categories were all independent factors for predicting hospital mortality in patients with ACS. However, we do not recommend the use of oral hypoglycaemic drugs for patients with ACS, since they might increase the risk of hyperglycaemia. Our findings also indicated a significant

Subgroup	No. of patients	Diabetes	non-Diabetes	OR(95%CI)	p value
Overall	3078	927	2151	0.92(0.71–1.20)	0.53
Age					
≥65	1811	550	1261	0.79(0.58–1.07)	0.13
<65	1267	377	890	1.46(0.86–2.48)	0.17
Sex					
Male	2033	577	1456	1.02(0.72–1.46)	0.89
Female	1045	350	695	0.75(0.50–1.12)	0.16
ACS categories					
AMI	2011	541	1407	1.05(0.79–1.39)	0.75
UA	1067	386	681	1.18(0.48–2.91)	0.72
Prior MI					
Yes	296	107	189	0.99(0.42–2.33)	0.99
No	2782	820	1962	0.92(0.69–1.21)	0.53
Hypertension					
Yes	1661	538	1123	1.26(0.61–2.58)	0.53
No	1417	389	1028	0.98(0.46–2.06)	0.95
Heart failure					
Yes	1032	337	695	0.91(0.62–1.32)	0.61
No	2046	590	1456	0.87(0.60–1.27)	0.48
Hyperlipidaemia					
Yes	822	298	524	1.69(0.97–2.95)	0.06
No	2256	629	1627	0.81(0.59–1.10)	0.17
Cerebral infarction					
Yes	105	38	67	0.60(0.18–2.03)	0.41
No	2973	889	2084	0.93(0.71–1.22)	0.62
Aspirin					
Yes	1538	509	1029	0.82(0.52–1.27)	0.37
No	1540	418	1122	1.08(0.77–1.49)	0.7
ACE inhibitor					
Yes	1265	336	929	1.03(0.54–1.97)	0.93
No	1813	591	1222	0.81(0.61–1.09)	0.17
Clopidogrel					
Yes	635	219	416	1.05(0.56–1.98)	0.88
No	2443	708	1735	0.91(0.68–1.22)	0.53
Diuretic					
Yes	1650	559	1091	0.82(0.55–1.22)	0.32
No	1428	368	1060	1.11(0.78–1.59)	0.56
Statin					
Yes	1381	444	937	0.87(0.49–1.55)	0.64
No	1697	483	1214	0.99(0.73–1.34)	0.96
glucose_{max}					
≥11.1	1218	624	594	0.42(0.31–0.57)	<0.001
<11.1	1860	303	1557	0.98(0.55–1.76)	0.96

Figure 3 Subgroup analysis of diabetes group and non-diabetes group. ACS, acute coronary syndrome; AMI, acute myocardial infarction; MI, myocardial infarction; UA, unstable angina.

relationship between level 3 and level 4 with higher mortality, relative to level 1, whereas level 2 showed no statistically significant difference. This may be attributed to the symmetrical mortality corresponding to the blood glucose range in level 1 and level 2, which represented as first decreased then increase.

Furthermore, we evaluated the optimal cut-off values of serum glucose_{max} during hospitalisation in patients with ACS and used them to predict hospital mortality. However, we did not evaluate the prognostic effect of blood glucose on admission as reported in previous studies.²⁹ To the best of our knowledge, this is the first study analysing glucose_{max} value in patients with ACS during hospitalisation and might provide a reference for the upper limit of blood glucose control in future patients. Specifically, we divided patients with ACS into five groups according to disease, then compared AUC and cut-off values across each group. Results indicated that glucose_{max} in the non-diabetes group had the best predictive efficacy, with AUC and cut-off values of 0.754 and 11.3 mmol/L, respectively. These results indicated that even an increase in blood glucose of patients with ACS, without diabetes, was also an important indicator of increased mortality. The cut-off value was significantly higher in the diabetes (15.8 mmol/L) than non-diabetes group (11.3 mmol/L), suggesting a different management strategy of glucose for patients with and without diabetes. We also found that among patients whose blood glucose_{max} ≥ 11.1 mmol/L, the mortality of the non-diabetes group was significantly higher than the diabetes group. However, there was no significant difference in mortality between the two groups in patients with blood glucose_{max} < 11.1 mmol/L. There are several interpretations for this condition. On the one hand, in this study, patients with diabetes were diagnosed based on their previous medical history when they were admitted to the hospital, and non-diabetes patients were also identified based on no previous history of diabetes. However, some non-diabetes patients may have a significant increase in blood glucose before admission, which was not known by patients. On the other hand, due to the stress state caused by ACS, patients without a history of diabetes might have developed hyperglycaemia during hospitalisation, which resulted in higher mortality in non-diabetes patients.

This study had some limitations. First, being a retrospective study, the independent link between hyperglycaemia and mortality may not necessarily equate to a causal relationship. Second, we only evaluated the relationship between maximum blood glucose and mortality during hospitalisation, which may cause a deviation in the conclusion. Third, it is possible that multiple factors may increase mortality. Lastly, maximum blood glucose levels may be affected by several factors, such as composition and duration of a meal and use or lack of hypoglycaemic drugs. These factors were not evaluated in the current study.

CONCLUSIONS

In summary, our findings indicated that mortality first decreased, then rose with increase in blood glucose levels. Patients with glucose_{max} ≥ 11.5 mmol/L exhibited a significant association with increased mortality in ACS. This association showed a 'tick'-type relationship. Among patients with significantly elevated blood glucose, the mortality of non-diabetes patients was significantly higher than diabetes patients. Based on these findings, hospitalised blood glucose levels in patients with ACS may be an important tool for stratifying potential risk, hence could be used to guide development of treatment approaches. ACS patients without diabetes need a more robust blood glucose management strategy, relative to diabetic counterparts. However, further studies are needed to determine whether treatment or correction of hyperglycaemia may reduce mortality in patients with ACS.

Contributors JQ and XL: responsible for data analysis and writing of the manuscript. LK and FC: responsible for data analysis. JQ: responsible for study data extraction. XL and JQ: statistician and responsible for data analysis. LC: responsible for data validation. All authors have read, revised and approved the final manuscript.

Funding This study was supported by the National Natural Science Foundation of China (Grant No. 81670403), Shanghai Science and Technology Committee (NO. 18411950300, 19XD1403300, and 19411963200).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Laboratory for Computational Physiology at the Massachusetts Institute of Technology.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Full data set available from the corresponding author. However, reanalysis of the full data need to be approved by Medical Information Mart for Intensive Care III Institute.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Xuebo Liu <http://orcid.org/0000-0003-3410-7204>

REFERENCES

- 1 Singh A, Museedi AS, Grossman SA. *Acute coronary syndrome*, 2020.
- 2 Viana MV, Moraes RB, Fabbrin AR, *et al.* [Assessment and treatment of hyperglycemia in critically ill patients]. *Rev Bras Ter Intensiva* 2014;26:71–6.
- 3 Jacobi J, Bircher N, Krinsley J, *et al.* Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. *Crit Care Med* 2012;40:3251–76.

- 4 Finney SJ, Zekveld C, Elia A, *et al.* Glucose control and mortality in critically ill patients. *JAMA* 2003;290:2041–7.
- 5 Bartnik M, Rydén L, Ferrari R, *et al.* The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro heart survey on diabetes and the heart. *Eur Heart J* 2004;25:1880–90.
- 6 Barton J, Kaski JC. The management of stress hyperglycaemia in patients experiencing acute coronary syndrome: a topic worth revisiting. *Eur Heart J Cardiovasc Pharmacother* 2020;6:126–7.
- 7 Zhao Q, Zhang T, Cheng Y, *et al.* Prognostic significance of relative hyperglycemia after percutaneous coronary intervention in patients with and without recognized diabetes. *Curr Vasc Pharmacol* 2020 doi:10.2174/1570161118666200317145540
- 8 Shin S-H, Claggett B, Pfeffer MA, *et al.* Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. *Eur J Heart Fail* 2020;22:1133–43.
- 9 Kosiborod M. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. *Endocrinol Metab Clin North Am* 2018;47:185–202.
- 10 Kosiborod M, Rathore SS, Inzucchi SE, *et al.* Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. *Circulation* 2005;111:3078–86.
- 11 Foo K, Cooper J, Deaner A, *et al.* A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. *Heart* 2003;89:512–6.
- 12 Winkelmann M, Butz AL, Clausen J-D, *et al.* Admission blood glucose as a predictor of shock and mortality in multiply injured patients. *Sicot J* 2019;5:17.
- 13 Hao Y, Lu Q, Li T, *et al.* Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention. *BMC Cardiovasc Disord* 2017;17:6.
- 14 Ceriello A. Acute hyperglycaemia: a 'new' risk factor during myocardial infarction. *Eur Heart J* 2005;26:328–31.
- 15 Ferroni P, Basili S, Falco A, *et al.* Platelet activation in type 2 diabetes mellitus. *J Thromb Haemost* 2004;2:1282–91.
- 16 Johnson AEW, Pollard TJ, Shen L, *et al.* MIMIC-III, a freely accessible critical care database. *Sci Data* 2016;3:160035.
- 17 Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 2013;17:204.
- 18 Chen P-C, Chua S-K, Hung H-F, *et al.* Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. *J Diabetes Investig* 2014;5:80–6.
- 19 Stranders I, Diamant M, van Gelder RE, *et al.* Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. *Arch Intern Med* 2004;164:982–8.
- 20 Gerbaud E, Darier R, Montaudon M, *et al.* Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. *Diabetes Care* 2019;42:674–81.
- 21 Huberlant V, Preiser J-C. Year in review 2009: Critical Care--metabolism. *Crit Care* 2010;14:238.
- 22 McCowen KC, Malhotra A, Bistrian BR. Stress-Induced hyperglycemia. *Crit Care Clin* 2001;17:107–24.
- 23 Senthinathan A, Kelly V, Dzingina M, *et al.* Hyperglycaemia in acute coronary syndromes: summary of NICE guidance. *BMJ* 2011;343:d6646.
- 24 Wong VW, Mardini M, Cheung NW, *et al.* High-Dose insulin in experimental myocardial infarction in rabbits: protection against effects of hyperglycaemia. *J Diabetes Complications* 2011;25:122–8.
- 25 Chaudhuri A, Janicke D, Wilson MF, *et al.* Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. *Circulation* 2004;109:849–54.
- 26 Cheng AYY, Houlden RL, Meltzer SJ. In-hospital diabetes management. *Can J Diabetes* 2014;38:71–2.
- 27 Cheng AYY, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. *Can J Diabetes* 2013;37 Suppl 1:S1–3.
- 28 Angeli F, Reboldi G, Garofoli M, *et al.* Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. *Curr Cardiol Rep* 2012;14:601–10.
- 29 Planer D, Witzensbichler B, Guagliumi G, *et al.* Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. *Int J Cardiol* 2013;167:2572–9.